Developer docs
API playgroundTry for free, no card

Search company profiles

Serengen

Full company profile

uuid003bb24

Namestring
Serengen
Legal namestring
Serengen GmbH
Websiteurl
serengen.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Serengen GmbH is a Dortmund-based biotech services company founded in summer 2019 that commercializes proprietary DNA-Encoded Library (DEL) technology originally developed at the Technical University of Dortmund. The company synthesizes and screens custom DELs for pharmaceutical companies, biotechnology firms, and academic/research organizations seeking faster and more economical unbiased hit identification in early-stage drug discovery.

Its core offering comprises two integrated services: customised DEL synthesis (delivered in three design modes — diversity-focused unbiased, target-focused structure-enabled, and hit-expansion ligand-enabled) and DEL selection screening using affinity matrix screening with enrichment calculation and double-control methodology. The underlying technology is differentiated by a novel encoding strategy based on stabilised DNA, a Double Fidelity System that removes by-products and reduces false positives/negatives, and limitation-free DNA-compatible chemistry intended to produce truly druglike, tractable hits that can be fed directly into lead generation.

Serengen operates as a B2B professional services company using direct enterprise sales, content marketing, and industry conferences (e.g., BIO-Europe 2023). Pricing is not publicly disclosed and is negotiated per project, with the company signalling "flexible business models." In August 2023, Serengen entered a strategic partnership with Deargen to add AI-driven drug-target interaction prediction (DearDTI) to its workflow. The company is privately held, has no disclosed external funding rounds or patents in the source data, and operates with a team of approximately five.

Short descriptiontext

Serengen GmbH is a Dortmund-based biotech services company that designs and screens custom DNA-Encoded Libraries for pharmaceutical, biotechnology, and academic clients to accelerate unbiased hit identification in early drug discovery.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersDortmund, Germany
HQ citystring
Dortmund
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
DNA-encoded libraries, drug discovery services, hit identification, DEL synthesis, DEL screening
Industry2 codes
PRIMARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Drug Discovery Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Customised DEL Synthesis
TypeProfessional Services
Description

Serengen synthesises DNA-Encoded Libraries tailored to individual drug discovery projects, offering unbiased design (diversity-focused DEL), structure-enabled design (target-focused DEL), and ligand-enabled design (hit-expansion DEL).

serengen.com
2DEL Selection Screening
TypeProfessional Services
Description

Provides affinity matrix screening services with enrichment calculation and double control for a wide range of proteins including membrane-bound proteins, PPIs, enzymes, and transcription factors.

serengen.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Serengen is a biotech company that synthesises and screens custom DNA-Encoded Libraries (DEL) for pharmaceutical, biotech, and research clients. Its proprietary limitation-free chemistry delivers druglike, tractable hits for early-stage drug discovery, enabling fast and cost-efficient unbiased hit identification.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Low hit-to-lead attrition rate due to truly druglike tractable hits
Product overview1 text field

Serengen offers a unified DEL technology platform comprising two integrated services: Customised DNA-Encoded Library (DEL) Synthesis and DEL Selection Screening. Their proprietary technology overcomes traditional DEL limitations by enabling limitation-free chemistry that delivers truly druglike, tractable hits. The platform supports unbiased design (diversity-focused DEL), structure-enabled design (target-focused DEL), and ligand-enabled design (hit-expansion DEL) for diverse molecular classes including small molecules, short peptides, peptidomimetics, and macrocycles, targeting membrane-bound proteins, PPIs, enzymes, and transcription factors.

Product and service2 records
1Customised DNA-Encoded Library (DEL) Synthesis
CategoryCore Service
Description

Custom synthesis of DNA-Encoded Libraries tailored to individual drug discovery projects using limitation-free chemistry to deliver druglike, tractable hits that feed directly into lead generation. Supports unbiased (diversity-focused), structure-enabled (target-focused), and ligand-enabled (hit-expansion) DEL design for pharma, biotech, and research organisations.

2DEL Selection Screening
CategoryCore Service
Description

Unbiased DEL screening service using affinity matrix screening across a wide range of proteins including membrane-bound proteins, PPIs, enzymes, and transcription factors, with enrichment calculation and double-control methodology to identify high-quality hits.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-08-29
Description

Strategic partnership integrating Serengen's novel DNA-Encoded Library (DEL) technology with Deargen's AI-driven drug discovery platform (DearDTI). The collaboration aims to accelerate drug discovery by combining DEL technology with Artificial Intelligence, enhancing efficiency and success rates in drug development. Both companies share the goal of offering valuable insights to clients and seeking innovative drug discovery solutions.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Serengen

Drug Discovery Servicesserengen.com

Serengen GmbH is a Dortmund-based biotech services company that designs and screens custom DNA-Encoded Libraries for pharmaceutical, biotechnology, and academic clients to accelerate unbiased hit identification in early drug discovery.

What Serengen does

Serengen GmbH is a Dortmund-based biotech services company founded in summer 2019 that commercializes proprietary DNA-Encoded Library (DEL) technology originally developed at the Technical University of Dortmund. The company synthesizes and screens custom DELs for pharmaceutical companies, biotechnology firms, and academic/research organizations seeking faster and more economical unbiased hit identification in early-stage drug discovery.

Its core offering comprises two integrated services: customised DEL synthesis (delivered in three design modes — diversity-focused unbiased, target-focused structure-enabled, and hit-expansion ligand-enabled) and DEL selection screening using affinity matrix screening with enrichment calculation and double-control methodology. The underlying technology is differentiated by a novel encoding strategy based on stabilised DNA, a Double Fidelity System that removes by-products and reduces false positives/negatives, and limitation-free DNA-compatible chemistry intended to produce truly druglike, tractable hits that can be fed directly into lead generation.

Serengen operates as a B2B professional services company using direct enterprise sales, content marketing, and industry conferences (e.g., BIO-Europe 2023). Pricing is not publicly disclosed and is negotiated per project, with the company signalling "flexible business models." In August 2023, Serengen entered a strategic partnership with Deargen to add AI-driven drug-target interaction prediction (DearDTI) to its workflow. The company is privately held, has no disclosed external funding rounds or patents in the source data, and operates with a team of approximately five.

Serengen firmographics

Firmographics
Name
Serengen
Legal name
Serengen GmbH
Website
https://serengen.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
Serengen GmbH is a Dortmund-based biotech services company that designs and screens custom DNA-Encoded Libraries for pharmaceutical, biotechnology, and academic clients to accelerate unbiased hit identification in early drug discovery.
Ownership category
akta.pro rank

Serengen industry classification

Industry
Product category
Drug Discovery Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • DNA-encoded libraries
  • Drug discovery services
  • Hit identification
  • DEL synthesis
  • DEL screening

Where Serengen is headquartered

Location

Headquarters

HQ city
Dortmund
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Serengen business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Customised DEL Synthesis: Serengen synthesises DNA-Encoded Libraries tailored to individual drug discovery projects, offering unbiased design (diversity-focused DEL), structure-enabled design (target-focused DEL), and ligand-enabled design (hit-expansion DEL).
  2. DEL Selection Screening: Provides affinity matrix screening services with enrichment calculation and double control for a wide range of proteins including membrane-bound proteins, PPIs, enzymes, and transcription factors.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Serengen product offering

Product offering

Core offering

Serengen is a biotech company that synthesises and screens custom DNA-Encoded Libraries (DEL) for pharmaceutical, biotech, and research clients. Its proprietary limitation-free chemistry delivers druglike, tractable hits for early-stage drug discovery, enabling fast and cost-efficient unbiased hit identification.

Product overview

Serengen offers a unified DEL technology platform comprising two integrated services: Customised DNA-Encoded Library (DEL) Synthesis and DEL Selection Screening. Their proprietary technology overcomes traditional DEL limitations by enabling limitation-free chemistry that delivers truly druglike, tractable hits. The platform supports unbiased design (diversity-focused DEL), structure-enabled design (target-focused DEL), and ligand-enabled design (hit-expansion DEL) for diverse molecular classes including small molecules, short peptides, peptidomimetics, and macrocycles, targeting membrane-bound proteins, PPIs, enzymes, and transcription factors.

Differentiator

Problem solved

Functional benefit

Products and services

  • Customised DNA-Encoded Library (DEL) Synthesis Custom synthesis of DNA-Encoded Libraries tailored to individual drug discovery projects using limitation-free chemistry to deliver druglike, tractable hits that feed directly into lead generation. Supports unbiased (diversity-focused), structure-enabled (target-focused), and ligand-enabled (hit-expansion) DEL design for pharma, biotech, and research organisations.
  • DEL Selection Screening Unbiased DEL screening service using affinity matrix screening across a wide range of proteins including membrane-bound proteins, PPIs, enzymes, and transcription factors, with enrichment calculation and double-control methodology to identify high-quality hits.

Quantifiable outcome

  • Low hit-to-lead attrition rate due to truly druglike tractable hits

Companies that use Serengen

Customer profile

Segments3 records

Ideal customer profiles3 records

Serengen technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Serengen partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • DeargencoreStrategic or Co-development Partner · 29 August 2023Strategic partnership integrating Serengen's novel DNA-Encoded Library (DEL) technology with Deargen's AI-driven drug discovery platform (DearDTI). The collaboration aims to accelerate drug discovery by combining DEL technology with Artificial Intelligence, enhancing efficiency and success rates in drug development. Both companies share the goal of offering valuable insights to clients and seeking innovative drug discovery solutions.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Serengen competitors and assessment

Company assessment

Market position

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Serengen social profiles

Digital presence

Serengen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Serengen leadership team

Management profile

Number of profiles

Profiles2 records

Serengen funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Serengen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Serengen

What does Serengen do?

Serengen is a biotech company that synthesises and screens custom DNA-Encoded Libraries (DEL) for pharmaceutical, biotech, and research clients. Its proprietary limitation-free chemistry delivers druglike, tractable hits for early-stage drug discovery, enabling fast and cost-efficient unbiased hit identification.

Is Serengen a public or private company?

Serengen is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Serengen founded?

Serengen was founded in 2019. It employs 1 to 10 people.

Where is Serengen based?

Serengen is headquartered in Dortmund, Germany, in the Europe region.

How does Serengen make money?

Two revenue lines are on record. Customised DEL Synthesis are the primary driver. The others are DEL Selection Screening.

Does Serengen have an API?

No public API is recorded for Serengen.

What industry is Serengen in?

Serengen's product category is Drug Discovery Services. Its primary akta.pro industry code is HLAAAIAL, Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals